These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3480046)

  • 1. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
    Jones WG; Fosså SD; Bono AV; Klijn JG; De Pauw M; Sylvester R
    Cancer Treat Rep; 1987 Dec; 71(12):1317-8. PubMed ID: 3480046
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
    Jones WG; Mattsson W
    Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: a phase II study.
    Izbicki RM; Amer MH; Al-Sarraf M
    Cancer Treat Rep; 1979 Jun; 63(6):999-1001. PubMed ID: 380805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.
    Petrioli R; Fiaschi AI; Francini E; Pascucci A; Francini G
    Cancer Treat Rev; 2008 Dec; 34(8):710-8. PubMed ID: 18620815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly chemotherapeutic regimen in metastatic prostate cancer.
    Burk K
    Prog Clin Biol Res; 1989; 303():261-75. PubMed ID: 2674989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
    Biganzoli L; Coleman R; Minisini A; Hamilton A; Aapro M; Therasse P; Mottino G; Bogaerts J; Piccart M
    Crit Rev Oncol Hematol; 2007 Jan; 61(1):84-9. PubMed ID: 17116400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.
    Moore MR; Troner MB; DeSimone P; Birch R; Irwin L
    Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
    Droz JP; Fargeot P; Laplaige P; Moran-Ribon A; Piot G
    Prog Clin Biol Res; 1987; 243B():235-42. PubMed ID: 3659022
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study.
    Richards B; Newling D; Fossa S; Bastable JR; Denis L; Jones WB; de Pauw M
    Cancer Treat Rep; 1983 Jun; 67(6):575-7. PubMed ID: 6861163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical evaluation of 4'-epi-doxorubicin.
    Hurteloup P; Cappelaere P; Armand JP; Mathé G
    Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
    Fosså SD; Wik B; Bae E; Lien HH
    Cancer Treat Rep; 1982 May; 66(5):1219-21. PubMed ID: 6952962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group.
    Carlson RW; Williams RD; Billingham ME; Kohler M; Torti FM
    Cancer Treat Rep; 1987; 71(7-8):767-8. PubMed ID: 3607787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.